Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DA-EPOCH-R in Untreated Aggressive CD20+ B-Cell NHL
NCT00032019Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Feb 2002
- Primary completion
- Dec 2004
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by Cancer and Leukemia Group B. Started Feb 2002; status: completed.
02
Drugs
rituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT00032019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00032019.